Activity and acceptability of piribedil in Parkinson's disease: a multicentre study (original) (raw)

Summary

Several controlled trials have shown that the dopamine agonist, Trivastal (piribedil), is active in the treatment of Parkinson's disease, particularly with regard to tremor. To determine its efficacy as monotherapy in patients previously untreated with levodopa, a 3-month multicentre study was conducted with Trivastal 50 mg LP in 113 patients with idiopathic Parkinson's disease. The study population consisted of 66 men and 47 women, aged 63.1, SD 0.6 (43–79) years with a 2.1, SD 0.2 (1–15) year history of Parkinson's disease. Mean disease stage was 1.82 (1–4) by the Hoehn and Yahr classification. Tremor was the predominant clinical feature in 42 patients; the remaining 71 patients displayed the full parkinsonian syndrom. Trivastal 50 mg LP was prescribed stepwise up to doses of 150–250 (207, SD 6.4) mg/day at the end of 3 months. No concomitant antiparkinsonian medication was given. Patients were clinically assessed at 1, 2 and 3 months on the Webster scale, a specific tremor scale and the HARD depression scale. Mean results were as follows in the 90 patients completing the study. On the Webster scale, tremor fell from 1.7 to 1 (−41%,P<0.001), bradykinesia from 1.5 to 0.8 (−47%,P<0.001) and rigidity from 1.3 to 0.9 (−31%,P < 0.001); on the specific scale, rest tremor decreased in daily duration and amplitude from 3.9 to 2.4 (−39%,P < 0.001) and from 2.9 to 2.1 (−35%,P < 0.001), respectively. The 32 patients in whom tremor was the predominant feature improved their total score on the Webster scale from 5.8 to 4.7 (−19%,P<0.05) and their tremor score from 1.7 to 1.2 (−29%,P < 0.05). The 58 patients with the full parkinsonian syndrom improved their total Webster score from 11.8 to 6.9 (−42%,P < 0.001). Eight of the ten items on the scale were significantly reduced, from between 33% (facial expression) to 53% (manual bradykinesia). The depression rating fell from 10.2 to 7.3 (P < 0.001), the most marked improvement being in mood and inhibition. In conclusion, monotherapy with Trivastal 50 mg LP at a mean dose of 200 mg/day is effective within 1 month regarding the major features of Parkinson's disease.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Arbuthnott GW, Murray LG (1975) Dopamine receptor agonists in psychiatric disease. Adv Neurol 9:345–348
    Google Scholar
  2. Butterworth RF, Poignant JC, Barbeau A (1975) Apomorphine and piribedil in rats: biochemical and pharmacologic studies. Adv Neurol 9:207–226
    Google Scholar
  3. Camanni F, Massara F, Molinatti GM,Muller EE, Fassio V (1975) Effect of five dopaminergic drugs on plasma growth hormone levels in acromegalic subjects. Neuroendocrinology 19:227–240; Ric Sci Educ Permanente [Suppl 1]: 100
    Google Scholar
  4. Chase TN, Woods AC, Glaubiger GA (1974) Parkinson's disease treated with a suspected dopamine receptor agonist. Arch Neurol 30:383–386
    Google Scholar
  5. Corrodi H, Fuxe K, Ungerstedt U (1971) Evidence for a new type of dopamine receptor stimulating agent. J Pharm Pharmacol 23:989–991
    Google Scholar
  6. Corrodi H, Farnebo LO, Fuxe K, Hamberger B, Ungerstedt U (1972) ET 495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors. Eur J Pharmacol 20:195–204
    Google Scholar
  7. Daniel WW (1978) Applied nonparametric statistics. Houghton Mifflin, Boston
    Google Scholar
  8. Dourish CT (1983) Piribedil: behavioral neurochemical and clinical profile of a dopamine agonist. Prog Neuropsychopharmacol 7:3–27
    Google Scholar
  9. Feigenson JS, Sweet RD, McDowell FM (1976) Piribedil: its synergistic effect in multi-drug regimens for parkinsonism. Neurology 26:430–433
    Google Scholar
  10. Ferreri M, Cousin J, Ruffin JC, Albi JM (1986) Validation du diagramme HARD par la MADRS. Encephale 12:343–350
    Google Scholar
  11. Goldstein M, Battista AF, Ohmoto T, Anagnoste B, Fuxe K (1973) Tremor and involuntary movements in monkeys: effect ofl-dopa and of a dopamine receptor stimulating agent. Science 179:816
    Google Scholar
  12. Hall MD, Jenner P, Marsden CD (1983) Differential labelling of dopamine receptors in rat brain in vivo: comparison of [3H]piribedil,3H]S 3608 and [3H]N, n-propyl-norapomorphine. Eur J Pharmacol 87:85–94
    Google Scholar
  13. Hoehn M, Yahr M (1967) Parkinsonism onset progression and mortality. Neurology 17:427–442
    Google Scholar
  14. Mayeux R, Stern Y, Rosen J, Leventhal J (1981) Depression, intellectual impairment and Parkinson disease. Neurology 31:645–650
    Google Scholar
  15. Mentenopoulos G, Katsarou Z, Bostantjopoulou S, Logothetis J (1989) Piribedil therapy in Parkinson's disease. Use of the drug in the retard form. Clin Neuropharmacol 12:23–28
    Google Scholar
  16. Ohmoto T (1975) Dyskinesia produced by L. Dopa in monkeys with resting tremor and tegmental lesions. Adv Neurol Sci 19:592–603
    Google Scholar
  17. Passouant P (1981) Effect on sleep of dopaminergic agonists. Apomorphine and others dopamino-mimetics. Clin Pharmacol 2:165–172
    Google Scholar
  18. Pfeiffer E (1975) A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 23:443–441
    Google Scholar
  19. Post RM, Gerner RH, Carman JS, Gillin JC, Jimerson DC, Goodwin FK, Bunney WE Jr (1978) Effects of a dopamine agonist piribedil in depressed patients. Arch Gen Psychiatry 35:609–615
    Google Scholar
  20. Rinne UK (1983) Dopamine agonists in the treatment of Parkinson's disease. Adv Neurol 37:141–150
    Google Scholar
  21. Rinne UK (1985) Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 35:1196–1198
    Google Scholar
  22. Rinne UK (1989) Lisuride a dopamine agonist in the treatment of early Parkinson's disease. Neurology 39:336–339
    Google Scholar
  23. Rondot P, Bathien N, Ribadeau-Dumas JL (1975) Indications of piribedil inl-dopa treated parkinsonian patients: physi0pathologic implications. Adv Neurol 9:373–381
    Google Scholar
  24. Rondot P, Recondo J de, Coignet A, Ziegler M (1984) Mental disorders in Parkinson's disease after treatment with L-Dopa. Adv Neurol 40:259–269
    Google Scholar
  25. Ruffin JC, Ferreri M (1984) Le diagramme HARD — un nouvel outil d'évaluation des états dépressifs en pratique courante. Br J Clin Pract (French edn) 2:31–37
    Google Scholar
  26. Sethy VH, Van Woert MH (1974) Regulation of striatal acetylcholine concentration by dopamine receptors. Nature 251:529–530
    Google Scholar
  27. Truelle JL, Chanelet J, Bastard J, Six P, Emile J (1977) Le piribédil agoniste dopaminergique. Etude clinique et électrophysiologique prolongée chez 60 parkinsoniens. Nouv Presse Med 6:2987–2990
    Google Scholar
  28. Vakil SD, Calne DB, Reid JL, Seymour CA (1973) Pyrimidilpiperonyl-piperazine (ET 495) in Parkinsonism. Adv Neurol 3:121–125
    Google Scholar
  29. Webster DD (1968) Clinical analysis of the disability in Parkinson's disease. Med Treat 5:257–282
    Google Scholar
  30. Winer BJ (1971) Statistical principles in experimental design. McGraw-Hill, New York
    Google Scholar
  31. Ziegler M (1989) Echelle du tremblement. In: Lacote M, Chevalier AM, Miranda A, Bleton JP (eds) Evaluation clinique de la fonction musculaire, 2nd edn. Maloine, Paris, p 486
    Google Scholar
  32. Ziegler M, Udo N, Bathien N, Rondot P (1987) Effets immédiats du piribédil sur le tremblement de repos. Precept Med 2:56–59
    Google Scholar
  33. Ziegler M, Spampinato U, Rondot P, Evrard Y, Falcoz C, Jeanniot JP, Ochsenbein E (1991) Cinétique plasmatique du piribédil par voie intraveineuse et corrélation avec le tremblement parkinsonien. JAMA [Suppl] 26–30

Download references

Author information

Authors and Affiliations

  1. Service de Neurologie, Centre Raymond Garcin, 2 bis, Rue d'Alésia, F-75674, Paris, France
    P. Rondot & M. Ziegler

Authors

  1. P. Rondot
    You can also search for this author inPubMed Google Scholar
  2. M. Ziegler
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Rondot, P., Ziegler, M. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study.J Neurol 239 (Suppl 1), S28–S34 (1992). https://doi.org/10.1007/BF00819564

Download citation

Key words